MedTrace Logo

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

NCT02072161 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2019-03-29

No results posted yet for this study

Summary

The purpose of this research study is to see how ETC-1002 is tolerated in the body and how ETC-1002 affects the levels of LDL-C (bad cholesterol) in patients receiving ongoing statin therapy.

Conditions

Interventions

DRUG

ETC-1002

ETC-1002 capsules, taken once daily oral

DRUG

Placebo

Placebo capsules, taken once daily oral

DRUG

Statin Therapy

Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Esperion Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Diane E MacDougall · Esperion Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02072161 on ClinicalTrials.gov